FDG-PET in Oncology
- FDG is a glucose look-alike that gets pulled into hungry cells and then stuck there, so it lights up tissue that's burning a lot of sugar — and most cancers are gluttons.
- PET (positron emission tomography) shows you metabolism, not anatomy; that's why it's almost always fused with CT, which supplies the map so you know where the bright spot lives.
- "Bright" is not the same as "cancer." Infection, inflammation, brown fat, and a busy brain or bladder all glow too. Context is everything.
- Its superpower is the whole-body sweep: staging, restaging, finding distant disease, and judging whether treatment is actually working.
Imagine you could spray a dye that only sticks to whichever cells in the body are eating the most — and then take one picture of the entire person from skull to thigh. That's the trick behind FDG-PET, and it's why a single scan can find a tumor you didn't know was there in a place nobody was looking.
The sugar-trap, in plain English
FDG stands for fluorodeoxyglucose. Strip away the syllables and it's just glucose wearing a disguise: a sugar molecule with a radioactive fluorine atom bolted on where one hydroxyl group should be.
Cells can't tell the difference at the front door, so they import FDG using the same glucose transporters they always use. But here's the elegant part — the cell starts to metabolize it, gets one step in, and then can't finish. The molecule gets phosphorylated and then jams, unable to go further down the assembly line or back out the door. So it accumulates. The more sugar a cell is gulping, the more FDG piles up inside it.
Most cancers run their metabolism hot and inefficient (a quirk metabolism nerds call the Warburg effect), so they hoard FDG and shine on the scan like a porch light. If the underlying physics of "how do we even see a radioactive tracer" feels shaky, take a two-minute detour through how nuclear medicine works first.
Why it's always glued to a CT
PET on its own is a fuzzy, glowing blob map. Beautiful, but anatomically clueless — it'll tell you something is metabolically loud without telling you whether it's a lymph node, a loop of bowel, or the patient's bladder.
So we fuse it with CT. The CT is the street map; the PET is the heat signature laid on top. Together you get PET/CT, where you can point at a bright spot and say not just "this is hot" but "this hot thing is a 1.2 cm node in the right hilum." The CT also does the math correction (attenuation correction) that makes the PET quantitative in the first place.
Reading the glow: SUV and "is this real?"
To put a number on brightness, we use the standardized uptake value (SUV) — basically a ratio that asks "how concentrated is the tracer here compared to if it had spread out evenly through the whole body?" A higher SUV means a hungrier, often more worrisome lesion. Resist the urge to treat SUV as a magic cancer thermometer with a hard cutoff; it shifts with scan timing, blood sugar, body size, and the scanner itself. It's a useful ruler, not a verdict.
Have the patient fast and keep blood sugar controlled before the scan. If the blood is swimming in real glucose, that glucose competes with FDG for the transporters, the tumor takes up less tracer, and your beautiful study turns muddy.
What FDG-PET is actually for
PET earns its keep across the whole arc of a cancer, not just at diagnosis. It pairs naturally with the broader logic of staging principles and TNM.
| Job | What PET adds |
|---|---|
| Staging | One whole-body sweep finds distant metastases that change the plan entirely. |
| Restaging | After treatment, distinguishes leftover live tumor from inert scar tissue. |
| Response assessment | Metabolism often falls before a mass physically shrinks — an early "it's working" signal. |
| Characterizing a lesion | A markedly avid mass is more suspicious than a quiet one (with big caveats below). |
That "metabolism drops before size does" point is why PET complements size-based response tools like RECIST: a tumor can still look identical on a ruler while its lights are already going out.
The trap: bright does not mean malignant
Here's the humbling part. FDG isn't loyal to cancer — it's loyal to any cell burning sugar. White blood cells fighting an infection are ravenous. So are inflamed joints, healing surgical beds, and granulomas. Brown fat in a chilly patient can light up the neck and shoulders like a string of holiday bulbs. The brain, heart, and urinary tract are normally bright and will fool you if you're not expecting them.
A glowing focus is a question, not an answer. Infection, inflammation, recent surgery, and physiologic uptake all mimic tumor; meanwhile some cancers are quietly FDG-cold and won't light up at all. Never call malignancy off brightness alone — correlate with the CT, the history, and the timing of any recent treatment.
That "some cancers don't glow" caveat matters: slow, low-grade, or mucinous tumors can run cool and slip past. PET is a brilliant search tool, not a perfect one. For the full rogues' gallery of these traps, see PET/CT pitfalls.
The one thing to remember
FDG-PET answers a different question than every other scan in the building. CT and MRI ask what does it look like; PET asks what is it doing. When you fuse those two questions — the anatomy and the metabolism — you can find cancer hiding in normal-sized structures and tell living tumor apart from dead scar. Just never forget that the light only means "this is busy," and busy has plenty of innocent explanations.